B of A Securities Reinstates Buy on Acumen Pharmaceuticals, Announces $14 Price Target
B of A Securities Reinstates Buy on Acumen Pharmaceuticals, Announces $14 Price Target
B of A 證券恢復對Acumen Pharmicals的買入，宣佈目標股價爲14美元
B of A Securities analyst Geoff Meacham reinstates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and announces $14 price target.
B of A Securities分析師傑夫·米查姆以買入恢復Acumen Pharmicals（納斯達克股票代碼：ABOS），並宣佈目標股價爲14美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。